Among the adverse effects of antipsychotics, which is the most common metabolic complication observed in patients on second-generation antipsychotics, particularly with clozapine and olanzapine?

Explanation

## Weight Gain and Metabolic Syndrome: The Most Common Metabolic Complication **Key Point:** Weight gain and metabolic syndrome are the **most frequent metabolic adverse effects** of second-generation antipsychotics (SGAs), occurring in 30–50% of patients, with clozapine and olanzapine carrying the highest risk. ### Epidemiology and Clinical Significance - **Incidence:** Weight gain occurs in 30–50% of SGA users; metabolic syndrome develops in 10–20%. - **Timeline:** Weight gain typically begins within 2–4 weeks and plateaus by 3–6 months. - **Clinical impact:** Increases cardiovascular morbidity, diabetes risk, and medication non-adherence. ### Mechanisms of Weight Gain with SGAs ```mermaid flowchart TD A[Second-Generation Antipsychotics]:::action --> B[H1 receptor antagonism]:::outcome A --> C[5-HT2C receptor antagonism]:::outcome A --> D[Muscarinic M3 antagonism]:::outcome B --> E[↑ Appetite, ↓ Satiety]:::outcome C --> F[↓ POMC neuron activity]:::outcome D --> G[↓ Metabolic rate]:::outcome E --> H[Weight gain & Metabolic syndrome]:::urgent F --> H G --> H ``` ### Risk Stratification: SGA Ranking by Metabolic Risk | Antipsychotic | Weight Gain Risk | Metabolic Risk | Glucose Dysregulation | |---|---|---|---| | **Clozapine** | Very High (8–10 kg) | Very High | High | | **Olanzapine** | Very High (7–9 kg) | Very High | High | | **Quetiapine** | High (5–7 kg) | Moderate–High | Moderate | | **Risperidone** | Moderate (3–5 kg) | Moderate | Low–Moderate | | **Aripiprazole** | Low (0–2 kg) | Low | Low | | **Ziprasidone** | Low (0–1 kg) | Low | Low | **High-Yield:** Clozapine and olanzapine are the **worst offenders** for metabolic complications; aripiprazole and ziprasidone are the **safest** metabolically. ### Components of Metabolic Syndrome (≥3 of 5 criteria) 1. Abdominal obesity (waist circumference). 2. Elevated fasting glucose (≥100 mg/dL) or diabetes. 3. Elevated triglycerides (≥150 mg/dL). 4. Reduced HDL cholesterol (<40 mg/dL in men, <50 mg/dL in women). 5. Elevated blood pressure (≥130/85 mmHg). ### Monitoring and Prevention **Clinical Pearl:** Baseline metabolic assessment (weight, BMI, waist circumference, fasting glucose, lipid panel, BP) is **essential** before initiating SGAs. Repeat monitoring at 4 weeks, 8 weeks, 12 weeks, then annually. **Mnemonic:** **WEIGHT** — Weight gain, Appetite ↑, Insulin resistance, Glucose dysregulation, Triglycerides ↑, Elevated BP. ### Management Strategies 1. **Prevention:** Choose metabolically safer agents (aripiprazole, ziprasidone, amisulpride). 2. **Lifestyle:** Counsel on diet, exercise, and weight monitoring. 3. **Pharmacological:** Metformin (500–1000 mg BD) reduces weight gain and improves glucose control. 4. **Drug switch:** If weight gain >7% baseline, consider switching to a lower-risk agent. **Warning:** Do NOT discontinue antipsychotics due to weight gain without psychiatric consultation; instead, optimize metabolic risk through monitoring and adjunctive interventions. [cite:KD Tripathi 8e Ch 12]